Search results for "Circulating biomarkers"

showing 8 items of 8 documents

Signature of Circulating Biomarkers in Recurrent Non-Infectious Anterior Uveitis. Immunomodulatory Effects of DHA-Triglyceride. A Pilot Study

2021

The purpose of this study was to identify circulating biomarkers of recurrent non-infectious anterior uveitis (NIAU), and to address the anti-inflammatory effects of triglyceride containing docosahexaenoic acid (DHA-TG). A prospective multicenter study was conducted in 72 participants distributed into: patients diagnosed with recurrent NIAU in the quiescence stage (uveitis group (UG)

0301 basic medicineMedicine (General)medicine.medical_specialtyClinical BiochemistryÀcids grassos omega-3GastroenterologyArticlerecurrent anterior non-infectious uveitisUveitis03 medical and health scienceschemistry.chemical_compoundR5-9200302 clinical medicineOral administrationInternal medicineOmega-3 fatty acidsMedicineTriglicèridsStage (cooking)Triglyceridesomega-3 fatty acidsTriglyceridebusiness.industryInterleukintriglyceride of docosahexaenoic acidmedicine.diseasecytokinesCirculating biomarkers030104 developmental biologychemistryDocosahexaenoic acidUveïtis030221 ophthalmology & optometryTumor necrosis factor alphabusinessUveitisDiagnostics
researchProduct

Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients

2020

ABSTRACT In the era of immunotherapies there is an urgent need to implement the use of circulating biomarkers in clinical practice to facilitate personalized therapy and to predict treatment response. We conducted a prospective study to evaluate the usefulness of circulating exosomal-PD-L1 in melanoma patients’ follow-up. We studied the dynamics of exosomal-PD-L1 from 100 melanoma patients by using an enzyme-linked immunosorbent assay. We found that PD-L1 was secreted through exosomes by melanoma cells. Exosomes carrying PD-L1 had immunosuppressive properties since they were as efficient as the cancer cell from which they derive at inhibiting T-cell activation. In plasma from melanoma patie…

0301 basic medicineOncologymedicine.medical_specialtyHistologyExosome03 medical and health sciences0302 clinical medicinePD-L1Internal medicinePD-L1/PD-1medicinefollow-upexosomelcsh:QH573-671Prospective cohort studyMelanomaimmune checkpointbiologylcsh:Cytologybusiness.industryMelanomaCell Biologymedicine.diseaseMicrovesiclesImmune checkpoint3. Good healthCirculating biomarkers030104 developmental biology030220 oncology & carcinogenesisCancer cellbiology.proteinbusinessResearch ArticleJournal of Extracellular Vesicles
researchProduct

Microcentrifuge or Automated Hematological Analyzer to Assess Hematocrit in Exercise? Effect on Plasma Volume Loss Calculations

2016

The assessment of plasma volume loss (∆PV) induced by exercise can be estimated from changes in hematocrit (Htc) and hemoglobin (Hb), and it is essential when investigating the metabolic or biologic response to exercise of circulating biomarkers. We aimed to ascertain whether the estimation of ∆PV may differ when Hb and Htc are determined by automated hematological analyzer (AHA) versus manual methods. Twenty-five healthy male subjects performed a maximal running incremental exercise. Blood samples were taken before exercise, immediately after exercise, and after a 30-min recovery. Hb and Htc (Htc-AHA) were determined by an AHA. Htc was also determined by microcentrifugation (Htc-M). The ∆P…

AdultMalemedicine.medical_specialtySpectrum analyzerSysmexAnalytical chemistryCentrifugationHematocritPlasma volumeIncremental exerciseHemoglobinsYoung Adult03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumanshemoconcentrationhealth care economics and organizationsplasma volumeAutomation LaboratoryexerciseBiologic responsemedicine.diagnostic_testChemistryDill and Costill equation030229 sport sciencesMiddle AgedhemoglobinHemoconcentrationDill and Costill equation; Sysmex; exercise; hemoconcentration; hemoglobin; plasma volumeHealthy Volunteersdigestive system diseasesComputer Science ApplicationsMedical Laboratory TechnologyCirculating biomarkersHematocritCardiologyHemoglobinBiomarkers030215 immunologySLAS Technology
researchProduct

Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls?

2015

Introduction: The discovery of molecular biomarkers and the advent of targeted therapies have led to a radical change in the treatment of several tumors, including NSCLC. In the last few years, the number of molecular biomarkers has rapidly increased, and a growing interest has been recently focused on their potential prognostic and predictive value in clinical settings. Areas covered: This review describes all the molecular biomarkers with prognostic and predictive value in NSCLC, including both clinically approved biomarkers, and emerging biomarkers under investigation in clinical trials. Liquid biopsy and applications of circulating biomarkers are also described. Expert opinion: The onco…

Oncologymedicine.medical_specialtyPathologyLung NeoplasmsOncogene Proteins Fusionmedicine.medical_treatmentClinical BiochemistryNSCLCprognostic biomarkersTargeted therapytissue biopsypredictive biomarkersInternal medicineCarcinoma Non-Small-Cell LungProto-Oncogene ProteinsDrug DiscoveryBiomarkers TumorMedicineHumansBiomarker discoveryLiquid biopsypredictive biomarkerprognostic biomarkerProtein Kinase InhibitorsPredictive biomarkerPharmacologyliquid biopsybusiness.industryDrug Discovery3003 Pharmaceutical Scienceliquid biopsy; NSCLC; predictive biomarkers; prognostic biomarkers; targeted therapy; tissue biopsy; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical ScienceProtein-Tyrosine KinasesPrognosistargeted therapyMolecular biomarkersPredictive valueClinical trialErbB ReceptorsCirculating biomarkersras Proteinsbusiness
researchProduct

Towards early risk biomarkers: serum metabolic signature in childhood predicts cardio-metabolic risk in adulthood

2019

AbstractCardiovascular diseases have their origin in childhood. Early biomarkers identifying individuals with increased risk for disease are needed to support early detection and to optimize prevention strategies. By applying machine learning approach on high throughput NMR-based metabolomics data, we identified metabolic predictors of cardiovascular risk in circulation in a cohort of 396 females, followed from childhood (mean age 11.2 years) to early adulthood (mean age 18.1 years). The identified childhood metabolic signature included three circulating biomarkers robustly associating with increased cardiovascular risk in early adulthood (AUC = 0.641 to 0.802, all p<0.01). These associa…

Oncologymedicine.medical_specialtybusiness.industryEarly detectionCardio metabolic riskMean ageDiseaseCirculating biomarkersIncreased riskInternal medicineCohortEarly adulthoodmedicinebusiness
researchProduct

Serum miRNAs in women affected by hyperandrogenic polycystic ovary syndrome: the potential role of miR-155 as a biomarker for monitoring the estropro…

2018

MicroRNAs can be used as very efficient circulating biomarkers. The role of microRNAs in polycystic ovary syndrome (PCOS) and the effects of antiandrogen therapy on microRNA expression is still not fully understood. A panel of serum microRNAs were retrotranscribed via looped reverse primer transcription specific for each miRNA and quantified via probe specific RT-PCR in 16 Caucasian hyperandrogenic PCOS women selected according to the Rotterdam criteria and in a subset of seven patients after four months of sequential reverse antiandrogenic therapy. All women recruited underwent an oral glucose tolerance test (OGTT) and a baseline total cholesterol, high density lipoproteins cholesterol, tr…

endocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismurologic and male genital diseasesSettore MED/13 - EndocrinologiamiR-155mir-15503 medical and health sciences0302 clinical medicineEndocrinologymicroRNAMedicineHumansAntiandrogen Therapy030219 obstetrics & reproductive medicineantiandrogenic therapy; biomarker; mir-155; Polycystic ovary syndrome; visceral adipose index; Endocrinology Diabetes and Metabolism; Endocrinology; Obstetrics and Gynecologybusiness.industryantiandrogenic therapyfungifood and beveragesObstetrics and GynecologyAndrogen Antagonistsvisceral adipose indexPolycystic ovaryCirculating biomarkersMicroRNAsCancer researchBiomarker (medicine)biomarkerFemalebusinesshormones hormone substitutes and hormone antagonistsBiomarkersPolycystic Ovary SyndromeGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct

Cardiorenal Syndrome: New Pathways and Novel Biomarkers

2021

Cardiorenal syndrome (CRS) is a multi-organ disease characterized by the complex interaction between heart and kidney during acute or chronic injury. The pathogenesis of CRS involves metabolic, hemodynamic, neurohormonal, and inflammatory mechanisms, and atherosclerotic degeneration. In the process of better understanding the bi-directional pathophysiological aspects of CRS, the need to find precise and easy-to-use markers has also evolved. Based on the new pathophysiological standpoints and an overall vision of the CRS, the literature on renal, cardiac, metabolic, oxidative, and vascular circulating biomarkers was evaluated. Though the effectiveness of different extensively applied biomark…

kidneyrenal injuryDiseaseCardiorenal syndromeReviewheartBioinformaticsBiochemistryMicrobiologyPathogenesisRenal injuryotorhinolaryngologic diseasesMedicineHumansNGALKIM-1Molecular Biologycardiorenal syndromeKidneymicroRNACardio-Renal Syndromebusiness.industryAcute kidney injuryChronic injurymedicine.diseasechronic renocardiac syndromenovel biomarkersPrognosisQR1-502proBNPCirculating biomarkersmedicine.anatomical_structureacute kidney injurybusinessAcute kidney injury; Cardiorenal syndrome; Chronic renocardiac syndrome; Heart; Kidney; KIM-1; MicroRNA; NGAL; Novel biomarkers; ProBNP; Renal injuryBiomarkersBiomolecules
researchProduct

High-Sensitivity C-Reactive Protein and Statin Initiation

2014

The assessment of cardiovascular risk and treatment of cardiovascular diseases are major public health issues worldwide. Inflammation is now recognized as a key regulatory process that links multiple risk factors for atherosclerosis. The substantial number of patients having cardiovascular events lack commonly established risk factors. The utility of high-sensitivity C-reactive protein (hsCRP), a circulating biomarker related to inflammation, may provide additional information in risk prediction. This review will consider the impact of hsCRP level on initiation of statin therapy.

medicine.medical_specialtyStatinmedicine.drug_classInflammationBioinformaticsMultiple risk factorsRisk AssessmentPredictive Value of TestsRisk FactorsmedicineHumanscardiovascular diseasesDyslipidemiasInflammationbiologybusiness.industryPublic healthC-reactive protein3. Good healthCirculating biomarkersC-Reactive ProteinTreatment OutcomeCardiovascular DiseasesPractice Guidelines as TopicPhysical therapybiology.proteinBiomarker (medicine)Statin therapyHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation Mediatorsmedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersAngiology
researchProduct